# A dedicated programme for cachexia and treatment toxicity research

Source: https://onco.cc/ideas/idea-fund-cachexia-programme/  
OnCo record `idea-fund-cachexia-programme` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Wasting and side-effects kill or stop treatment for a large share of patients but attract almost no dedicated funding. This would create a standing programme for them.

## Summary

A programme with its own review panel funds cachexia mechanisms (GDF15, inflammatory and neural circuits), interventional trials of anti-cachexia agents and nutrition and exercise bundles, and toxicity science (neuropathy, cardiotoxicity, cytopenias, cognitive effects) with biomarkers and prevention trials. Supportive-care research fails in general panels because it is judged as less innovative; a dedicated pot and reviewers who know the field fixes that. GDF15 antagonists reaching late-phase trials show the biology is tractable.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A dedicated programme at 2% of a national budget doubles registered interventional trials in cachexia and toxicity within five years and yields at least one approved supportive-care agent or validated toxicity-prevention strategy within ten.
- Rationale: Cachexia is implicated in up to a third of cancer deaths; the recent progress on GDF15 came from industry, not academia, because academic supportive-care research was starved. Dedicated programmes created fields in palliative care in the UK and in geriatric oncology in France.
- Proposed test: Portfolio audit, then launch and compare trial registrations, publications and industry co-investment in the supported area after five years with a matched neglected area.
- Maturity: speculative
- Actor: philanthropy

## Sources

- Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012): https://doi.org/10.1186/1471-2407-12-526

## Connected records

- ideas: [Structured exercise prescribed like a drug in all curative-intent cancer care](https://onco.cc/ideas/idea-exercise-as-adjuvant/), [Ten-year awards for scientists who commit to one hard problem](https://onco.cc/ideas/idea-fund-ten-year-hard-problem-awards/)
- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Geriatric assessment](https://onco.cc/technologies/geriatric-assessment/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials](https://onco.cc/key-papers/paper-sun-bmc-cancer/)
- roadmaps: [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-cachexia-programme.json